Healthcare Innovation Procurement Resource Hub

Healthcare Innovation Procurement Resource Hub

Pre-Commercial Procurement (PCP) and Public Procurement of Innovation (PPI) are strategic instruments that enable public authorities to stimulate the development and adoption of innovative solutions. In the healthcare sector, these tools are particularly relevant, as they support the acquisition of innovative products and services that transform the way healthcare is delivered, improving efficiency, sustainability, quality of care, and patient outcomes.

There are tons of information available on innovation procurement. This repository groups all key information and resources related to PCP and PPI in healthcare.

What will you find in this page?

What is Pre-commercial Procurement (PCP) in Healthcare?

Pre-commercial procurement (PCP) is a procurement procedure where public procurers buy research and development services from several suppliers competing in parallel to compare alternative solution approaches and identify the best value for money solutions that the market can deliver to address their needs. Research and development are split into phases (solution design, prototyping, original development and validation/testing of a limited set of first products) with the number of competing research and development providers being reduced after each phase.

The public buyer does not reserve the R&D results for its own use, but shares them with the economic operators under market conditions. The risks and benefits of the R&D are thus shared between the public buyer and the industry.

PCP does not entail the purchase of a finished product!

Why use a PCP?

The benefits of conducting a PCP as a public buyer:

  • Ability to address complex and unmet needs;
  • Closer contact with the market players and suppliers;
  • Sharing of risks and benefits between public buyer and suppliers;
  • Leads to better value for money in later procurement procedures, as you can filter out technological R&D risks of potential alternative solutions before committing to procuring a large scale commercial roll-out.

The benefits of participating in a PCP as a supplier:

  • Access to funded R&D: you do not have to carry the full financial risk yourself;
  • Early validation of your technology;
  • Faster route to the market;
  • Reduced commercial risk, as there is no obligation to deliver a finished product, only to carry out R&D activities.

 

When is a PCP appropriate?

When there is no suitable innovative solution on the market to address your unmet need, meaning that significant R&D is required.

 

PCP Process and Phases

  • PHASE 1: Solution design
  • PHASE 2: Prototype development
  • PHASE 3: Pilot testing and validation

During each of the PCP Phases, the performance of each participating provider will be monitored and evaluated against pre-defined criteria. After each Phase, the best scoring offers will be awarded a contract for the next Phase. The end of Phase 3 marks the end of the PCP procedure.

 

Key success factors

  • Clear definition of your unmet need;
  • Clear and outcome-oriented demand;
  • Strong patient involvement;
  • Open engagement with the market;
  • Well-designed evaluation criteria.

 

Legal framework

PCP is exempt from the EU Public Procurement Directives

❗PCPs must comply with the fundamental EU principles of transparency, equal treatment, non-discrimination and proportionality.

What is Public Procurement of Innovation (PPI) in Healthcare?

Public procurement of innovative solutions (PPI) is a procurement approach where the public sector uses its purchasing power to act as early adopter of innovative solutions which are not yet available on large scale commercial basis. It provides a large enough demand to incentivize the industry to invest in wide commercialisation to bring innovative solutions to the market with the quality and price needed for mass market deployment. This enables the public sector to modernise public services with better value for money solutions and provides growth opportunities for companies.

Why use a PPI?

Benefits of conducting a PPI as a public buyer:

  • Better value for money;
  • Access to innovative solutions that address arising needs with improved quality, efficiency and user experience;
  • Creates a clear demand for innovation, encouraging the industry to invest and scale innovative solutions.

Benefits of participating in a PPI as a supplier:

  • The public buyer serves as a first customer, providing early market traction;
  • Deploy and validate the solution at operational scale in real-life setting;
  • Facilitates scaling and repeatability, as public demand helps standardize solutions and opens opportunities for wider market uptake;
  • Credibility boost, supporting further commercialization and entry into new markets.

When is a PPI appropriate?

When innovative solutions already exist but are not yet widely adopted or commercialised, meaning that no new R&D is needed.

 

PPI Process

  1. Preparation: Define your unmet need, engage with the market and build a business case.

  2. Procurement: Choose the appropriate procedure (open, restricted, competitive procedure with negotiation, competitive dialogue or innovation partnership) as best-suited for the innovative solution desired. More flexible and dialogue-based procedures allow closer interaction with suppliers, helping to refine requirements, adapt solutions and reduce implementation risks when procuring innovative solutions.

  3. Deployment: Execute the contract and monitor the performance of the contractor.

Key success factors

  • Clear definition of your unmet need;
  • Clear and outcome-oriented demand;
  • Strong patient involvement;
  • Open engagement with the market.

Legal framework

PPIs must follow EU public procurement rules and corresponding national implementation provisions.

Most important are the 2014 Public Procurement Directives.

  1. Public sector: Directive 2014/24/EU of the European Parliament and of the Council of 26 February 2014 on public procurement and repealing Directive 2004/18/EC Text with EEA relevance
  2. Utilities: Directive – 2014/25 – EN – EUR-Lex; EUR-Lex – 02014L0025-20260101 – EN – EUR-Lex

These Directives establish the legal framework governing public procurement across the EU, including provisions that enable innovation-friendly procedures.

They introduce instruments such as the Innovation Partnership and clarify flexibility for functional specifications and competitive procedures.

Public hospitals and health authorities are considered contracting authorities under this Directive. It governs procurement of:

  • Medical technologies
  • Digital health solutions
  • Surgical, medical and diagnostic procedures
  • Pharmaceuticals (with specific considerations)
  • Health services contracts
  • Innovation partnerships
  • PCP/PPI-related procedures (when applicable)

It includes provisions enabling innovation-friendly tools such as:

  • Innovation Partnership (Article 31)
  • Competitive Dialogue
  • Competitive Procedure with Negotiation
  • Functional/Performance-based specifications

Pilot vs. Innovation Partnership vs. PCP/PPI: Key Differences Explained

The differences between Innovation Procurement (PCP/PPI), Innovation Partnership, and Pilots are not always clear in practice, but they differ substantially in ambition, legal framework, scalability, and market-shaping capacity. The table below provides a structured comparison to help decision-makers and procurers identify which approach best fits their objectives, the maturity of the solution, and the level of transformation they aim to achieve.

 

Dimension

Pilot

Innovation Partnership

Innovation Procurement (PCP / PPI)

Objective

Test / validate a specific solution

Develop and purchase innovative solution within one procedure

Develop or deploy solutions not fully available on the market

Length / Difficulty

Relatively short & lighter

Medium-High complexity

 High complexity, multi-phase

Market Influence Power

Limited, adopts existing or near-ready solution

Influences specific supplier development

Shapes the market; stimulates competition; creates future supply

Competition Level

Often single supplier

Competitive selection → then single partner(s)

Competitive phased process with multiple suppliers

Risk Distribution

Higher dependency on one supplier

Shared between buyer and selected partner

Risk shared across multiple suppliers

Scalability Potential

Scaling uncertain / not embedded structurally

Scalable within contracting authority

Designed for replication & broader adoption → systemic transformation

When NOT to Use

If systemic change or market shaping is required

If need is exploratory or unclear

If solution already fully available and standard procurement suffices

Complete Repository of EU Healthcare PCP and PPI Projects​

Project Name Instrument Health Topic Participating Countries
Nightingale PCP Patient monitoring (wearable, clinical) Netherlands, Germany, Sweden, Belgium, UK
ANTISUPERBUGS PCP Infection control, antimicrobial detection UK, Germany, Italy, Spain
DECIPHER PCP Electronic Health Records, patient monitoring Spain, UK, Italy
HSMONITOR PCP Remote health monitoring Turkey, Sweden, Croatia, Italy
PROEMPOWER PCP Diabetes management solution Turkey, Portugal, Spain, Bulgaria, Italy
TIQUE PCP Advance Heart Failure Integrated Care Spain, Sweden, Italy, UK, Israel
CRANE PCP Chronic patients integrated self-management Norway, Sweden, Spain, Denmark
Instand-NGS4P PCP Cancer NGS workflow standardisation Austria, Germany, Italy, Netherlands, UK, Slovenia
oncNGS PCP Oncology genomic diagnostics Belgium, Germany, Italy, Spain, France
eCARE PCP Frailty & emergency care Spain, Italy, Germany, Portugal
NYMPHA PCP Bipolar disorder management Italy, Denmark, Spain
STOPandGO PPI Telecare and telehealth for older people UK, Spain, Netherlands, Italy
RITMOCORE PPI Arrhythmia remote monitoring Spain, UK
HAPPI PPI Healthy ageing / assistive tech Ireland, Belgium, Italy, Greece, Germany, Spain, Portugal, Cyprus, France, Finland, Czechia, Sweden, UK, Norway
SILVER PCP Elderly independent living robotics UK, Denmark, Finland, Netherlands, Sweden
RaDAR PPI Rapid detection of antimicrobial resistance Spain, France, Italy
Thalea & Thalea II PCP & PPI Telemedicine for co-morbid patients Germany, Netherlands, Spain, Belgium, Finland

Guidelines for Healthcare Innovation Procurement (PCP/PPI)

European-level guidance provides the legal, strategic, and methodological foundation for implementing PCP and PPI in any domain field (environmental science, energy, transportation, urban mobility, healthcare….).

  • European Assistance for Innovation Procurement (EAFIP)
    • Provides technical assistance, training, and case studies to support contracting authorities in implementing innovation procurement. Although the support is not focused on innovation procurement in the healthcare sector specifically, it offers practical examples, templates, and lessons learned from real PCP and PPI projects that were carried out across Europe.
  • Health Innovation Procurement Adoption Tool (HIPAT)
    • Step-by-step guide on public procurement of innovation specific to healthcare. It includes curated resources and ad-hoc support services.

Funding Opportunities for Healthcare PCP and PPI Projects

EU-level funding and project databases: 

Innovation Procurement Communities and Networks in Europe

  • Competence Centers on Innovation Procurement: National organisations with the mandate to support the use of PCP/PPI (practical and/or financial assistance to public procurers in the preparation and/or implementation of PCP and PPI across all sectors of public interest).
  • Public Buyers Community: European Commission initiative dedicated to facilitating joint action in public purchasing across the EU.
  • Health Proc Europe: Non-profit interest group of European and Canadian hospital and health care procurement managers aiming to create the largest digital procurement ecosystem.
  • Procure4Health: Open community that encourages EU-wide adoption of innovation procurement.
  • Agora InnoHSupport: Interactive space designed to connect public procurers, suppliers, and investors in healthcare innovation procurement.
  • ECLIPSE | EuroQuity: Connects public procurers with innovators, investors, and other relevant stakeholders. Ecosystem specially focused on investors.

Notice that inactive forums and communities are not shown.

Navigating Innovation Procurement with Confidence: Guidance, Resources and Advisory Support

Understanding innovation procurement is the first step, implementing it is the real challenge. While this page brings together key knowledge and EU healthcare PCP/PPI projects, the Health Innovation Procurement Adoption Tool (HIPAT) helps you move from information to action. Through structured guidance, practical templates, and advisory support, HIPAT supports healthcare procurers in designing and launching successful PCP and PPI processes with clarity and confidence.

Ready to start your innovation procurement journey? Explore HIPAT and access the tools that will guide you step by step.

Submit Feedback

Propose a Service Provider